Novanta (NOVT) posted a net profit margin of 5.5%, slipping from 6.5% last year, after absorbing a one-time $26.0 million loss that weighed on its trailing 12-month earnings to September 26, 2025. While the company’s average annual earnings growth over the past five years was 7.1%, recent figures have reversed course, making this period a clear outlier. Looking ahead, forecasts call for 6.6% annual revenue growth and a rapid 51.5% annual earnings expansion. This sets up a sharp contrast with a share price now trading at $129.33, well above the $46.83 fair value estimate.

See our full analysis for Novanta.

Next up, we’ll put these headline results side by side with the major narratives shaping investor expectations to see where the numbers reinforce or challenge the story so far.

See what the community is saying about Novanta

Analysts expect Novanta’s profit margin will rise significantly from 6.4% today to 11.9% in three years, pointing to efficiency gains and improved product mix over time.

Within the analysts’ consensus view, operational improvements and supply chain strategies are noted as major catalysts expected to push gross and EBITDA margins higher in coming years.

Consensus narrative highlights targeted cost cuts, manufacturing regionalization, and a strategic push toward higher-margin recurring revenue as drivers of resilience in cash flows.

Despite this, current margin softness underscores how near-term gains remain closely tied to successful execution on these structural plans as well as full integration of acquisitions.

What stands out is how Novanta’s margin rebound targets compare with consensus confidence in sustained, above-market growth. See the full story in the Consensus Narrative.???? Read the full Novanta Consensus Narrative.

The latest guidance points to organic revenue growth flat to up just 1% for 2025, implying that most of the forward revenue gains are likely to come from further acquisitions rather than from existing core operations.

Consensus narrative flags a few structural risks that stem from this reliance on external deals:

Analysts call out how any slowdown in the pipeline of deals or integration hiccups could hamper management’s goal of consistent long-term revenue and earnings expansion.

With key segments like Precision Medicine seeing year-over-year declines as steep as 13% and trade uncertainty ongoing, consensus warns of possible margin and profit headwinds if external growth levers falter.

With Novanta currently trading at a P/E of 87.6x, which is well above both the industry average of 25x and the peer average of 22.7x, the stock price substantially overshoots the DCF fair value of $46.83 per share and benchmarks for its sector.

The analysts’ consensus narrative makes the case that agreeing with the $141.5 price target depends on believing that by 2028, Novanta will deliver $1.1 billion in revenue and sustain a future P/E of 48.1x, still double the sector median.

This leaves little room for earnings misses or slower growth. If margin expansion or acquisition synergies stall, the current premium could swiftly unwind.

Consensus points to the necessity for investors to “sense check” these bullish targets versus their own assumptions, as even small deviations could make today’s pricing look stretched.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Novanta on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a different take on the figures? Share your perspective and build your own narrative in just a few minutes. Do it your way

A great starting point for your Novanta research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Novanta relies heavily on acquisitions and is trading at an ultra-high valuation. This could leave investors exposed if revenue growth stalls or integration plans do not succeed.

For those seeking companies trading closer to fair value with less pricing risk, check out these 844 undervalued stocks based on cash flows that could offer stronger upside and reduced downside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com